

N-Formyl Peptide Receptor 2 - Pipeline Review, H2 2019

https://marketpublishers.com/r/N78BEB24822EEN.html

Date: December 2019

Pages: 32

Price: US\$ 3,500.00 (Single User License)

ID: N78BEB24822EEN

Abstracts

N-Formyl Peptide Receptor 2 - Pipeline Review, H2 2019

SUMMARY

According to the recently published report 'N-Formyl Peptide Receptor 2 - Pipeline Review, H2 2019'; N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) pipeline Target constitutes close to 8 molecules.

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - N-formyl peptide receptor 2 (FPR2) is a G-protein coupled receptor (GPCR) encoded by the FPR2 gene and is activated to regulate cell function by binding to a wide variety of ligands like N-Formylmethionine-containing oligopeptides such as N-Formylmethionine-leucyl-phenylalanine (FMLP), polyunsaturated fatty acid metabolite of arachidonic acid, lipoxin A4 (LXA4). FPR2 mediates responses to a wide range of polypeptides and proteins which may serve to promote inflammation.

The report 'N-Formyl Peptide Receptor 2 - Pipeline Review, H2 2019' outlays comprehensive information on the N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in N-Formyl Peptide Receptor 2 (FMLP Related



Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I and Preclinical stages are 2 and 6 respectively. Report covers products from therapy areas Cardiovascular, Central Nervous System, Immunology, Dermatology, Gastrointestinal, Infectious Disease, Metabolic Disorders and Oncology which include indications Inflammation, Alzheimer's Disease, Atherosclerosis, Atopic Dermatitis (Atopic Eczema), Cardiovascular Disease, Congestive Heart Failure (Heart Failure), Crohn's Disease (Regional Enteritis), Fungal Infections, Ischemia Reperfusion Injury, Ischemic Stroke, Metastatic Cancer, Multiple Sclerosis, Myocardial Infarction, Myocardial Ischemia, Staphylococcus aureus Infections and Type 2 Diabetes.

SCOPE

The report provides a snapshot of the global therapeutic landscape for N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2)

The report reviews N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics and enlists all their major and minor projects

The report assesses N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics based on mechanism of action (MoA), route of



administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Contents

Introduction

Global Markets Direct Report Coverage

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor

Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Overview

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor

Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor

Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor

Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Companies Involved in

Therapeutics Development

Bristol-Myers Squibb Co

CohBar Inc

Limulus Therapeutics Pty Ltd

NovaCell Technology Inc

ResoTher Pharma ApS

Trio Medicines Ltd

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor

Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Drug Profiles

Humanin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCP-112 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCP-70X - Drug Profile

Product Description

Mechanism Of Action



R&D Progress

RTP-025 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RTP-026 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize FPR-2 for Heart Failure and Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize FPR1 and FPR2 for Ischemia Reperfusion Injury - Drug

Profile

Product Description

Mechanism Of Action

R&D Progress

TR-8 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor

Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Dormant Products

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor

Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer



List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Bristol-Myers Squibb Co, H2 2019

Pipeline by CohBar Inc, H2 2019

Pipeline by Limulus Therapeutics Pty Ltd, H2 2019

Pipeline by NovaCell Technology Inc, H2 2019

Pipeline by ResoTher Pharma ApS, H2 2019

Pipeline by Trio Medicines Ltd, H2 2019

Dormant Projects, H2 2019

Discontinued Products, H2 2019



List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Bristol-Myers Squibb Co
CohBar Inc
Limulus Therapeutics Pty Ltd
NovaCell Technology Inc
ResoTher Pharma ApS
Trio Medicines Ltd



I would like to order

Product name: N-Formyl Peptide Receptor 2 - Pipeline Review, H2 2019
Product link: https://marketpublishers.com/r/N78BEB24822EEN.html

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/N78BEB24822EEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970